SCHEMBL20394161

SCHEMBL20394161

CCOC(=O)c1ccc(Oc2ncccc2-c2cnccc2Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 5/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
CYP1A2 P05177 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 1/20 0.44
POLB P06746 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPBWR1 P48145 1/20 0.42
MCHR1 Q99705 1/20 0.42
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394244 0.89 PDE10A (0.46) PDE10AKDM4ECCNCCDK8CYP1A2
SCHEMBL20394320 0.88 PDE10A (0.46) PDE10AKDM4ECCNCCDK8L3MBTL1
SCHEMBL20394485 0.87 PDE10A (0.52) PDE10AKDM4ECCNCCDK8MAPT
SCHEMBL18661529 0.86 PDE10A (0.60) PDE10AALDH1A1CCNCCDK8POLB
SCHEMBL20406628 0.84 PDE10A (0.57) PDE10AKDM4EALDH1A1CCNCCDK8
SCHEMBL20394192 0.83 MAPT (0.47) PDE10AKDM4EL3MBTL1MAPTNPBWR1
SCHEMBL25191466 0.77 ALDH1A1 (0.56) PDE10AKDM4EALDH1A1CYP1A2L3MBTL1
SCHEMBL30414735 0.77 ALDH1A1 (0.56) PDE10AKDM4EALDH1A1CYP1A2L3MBTL1
SCHEMBL11812647 0.76 TDP1 (0.50) ALDH1A1CYP1A2L3MBTL1MAPTPOLB
SCHEMBL2458300 0.76 PDE10A (0.53) PDE10AALDH1A1CYP1A2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA PDE10A 4605/4885KDM4E 2642/4885ALDH1A1 2994/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA PDE10A 4605/4885KDM4E 2642/4885ALDH1A1 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.